Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2015 1
2019 2
2020 4
2021 3
2022 6
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Palliative Radiotherapy for Symptomatic Locally Advanced Breast Cancer.
Hoeltgen L, Meixner E, Hoegen P, Sandrini E, Weykamp F, Forster T, Vinsensia M, Lang K, König L, Arians N, Fremd C, Michel LL, Smetanay K, Schneeweiss A, Wallwiener M, Debus J, Hörner-Rieber J. Hoeltgen L, et al. Among authors: michel ll. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231164537. doi: 10.1177/15330338231164537. Technol Cancer Res Treat. 2023. PMID: 37038619 Free PMC article.
Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1.
Bartkowiak K, Mossahebi Mohammadi P, Gärtner S, Kwiatkowski M, Andreas A, Geffken M, Peine S, Verpoort K, Scholz U, Deutsch TM, Michel LL, Schneeweiss A, Thewes V, Trumpp A, Müller V, Riethdorf S, Schlüter H, Pantel K. Bartkowiak K, et al. Among authors: michel ll. J Proteome Res. 2023 Apr 7;22(4):1213-1230. doi: 10.1021/acs.jproteome.2c00739. Epub 2023 Mar 16. J Proteome Res. 2023. PMID: 36926972
Relationship of Ki-67 index in biopsies of metastatic breast cancer tissue and circulating tumor cells (CTCs) at the time of biopsy collection.
Deutsch TM, Fischer C, Riedel F, Haßdenteufel K, Michel LL, Sütterlin M, Riethdorf S, Pantel K, Wallwiener M, Schneeweiss A, Stefanovic S. Deutsch TM, et al. Among authors: michel ll. Arch Gynecol Obstet. 2024 Jan;309(1):235-248. doi: 10.1007/s00404-023-07080-y. Epub 2023 Jul 22. Arch Gynecol Obstet. 2024. PMID: 37480379 Free PMC article.
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf AD, Lux MP, Huober J, Uhrig S, Taran FA, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Hein A, Belleville E, Untch M, Janni W, Fehm TN, Kolberg HC, Wallwiener D, Brucker SY, Schneeweiss A, Ettl J, Fasching PA, Michel LL. Huebner H, et al. Among authors: michel ll. Breast Cancer Res Treat. 2023 Jan;197(2):355-368. doi: 10.1007/s10549-022-06795-x. Epub 2022 Nov 21. Breast Cancer Res Treat. 2023. PMID: 36409394 Free PMC article.
Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs.
Berghoff AS, Liao Y, Karreman MA, Ilhan-Mutlu A, Gunkel K, Sprick MR, Eisen C, Kessler T, Osswald M, Wünsche S, Feinauer M, Gril B, Marmé F, Michel LL, Bago-Horvath Z, Sahm F, Becker N, Breckwoldt MO, Solecki G, Gömmel M, Huang L, Rübmann P, Thome CM, Ratliff M, Trumpp A, Steeg PS, Preusser M, Wick W, Winkler F. Berghoff AS, et al. Among authors: michel ll. Mol Cancer Res. 2021 Apr;19(4):688-701. doi: 10.1158/1541-7786.MCR-20-0863. Epub 2020 Dec 22. Mol Cancer Res. 2021. PMID: 33443114 Free PMC article.
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching PA, Solbach C, Schmutzler RK, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S; GBG and AGO-B. Schneeweiss A, et al. Among authors: michel ll. Eur J Cancer. 2022 Jan;160:100-111. doi: 10.1016/j.ejca.2021.10.011. Epub 2021 Nov 17. Eur J Cancer. 2022. PMID: 34801353 Clinical Trial.
Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer.
Meixner E, Hoeltgen L, Hoegen P, König L, Arians N, Michel LL, Smetanay K, Fremd C, Schneeweiss A, Debus J, Hörner-Rieber J. Meixner E, et al. Among authors: michel ll. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221118188. doi: 10.1177/15330338221118188. Technol Cancer Res Treat. 2022. PMID: 35950239 Free PMC article.
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Müller V, Hein A, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Beckmann MW, Schneeweiss A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Meyer J, Wurmthaler LA, Kurbacher CM, Wuerstlein R, Untch M, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Michel LL. Müller V, et al. Among authors: michel ll. Eur J Cancer. 2022 Sep;172:13-21. doi: 10.1016/j.ejca.2022.05.015. Epub 2022 Jun 18. Eur J Cancer. 2022. PMID: 35728342 Free article.
Stereotactic radiosurgery for brain metastases from pelvic gynecological malignancies: oncologic outcomes, validation of prognostic scores, and dosimetric evaluation.
Meixner E, Eichkorn T, Erdem S, König L, Lang K, Lischalk JW, Michel LL, Schneeweiss A, Smetanay K, Debus J, Hörner-Rieber J. Meixner E, et al. Among authors: michel ll. Int J Gynecol Cancer. 2022 Feb;32(2):172-180. doi: 10.1136/ijgc-2021-002906. Epub 2021 Nov 30. Int J Gynecol Cancer. 2022. PMID: 34848530
17 results